Marco Bua

3.9k citations

32 papers · 2.6k indexed · 1 hit paper · h-index 18

Hematology top 0.2%
Genetics top 0.2%
Rheumatology top 0.5%
Public Health, Environmental and Occupational Health top 10%
Pathology and Forensic Medicine top 5%

Co-authors: John M. Goldman Jane F. Apperley David Marín Dragana Milojković Alistair Reid Richard Szydlo Jamshid S. Khorashad Hugues de Lavallade
Topics: Chronic Myeloid Leukemia Treatments (26 papers)Chronic Lymphocytic Leukemia Research (25 papers)Eosinophilic Disorders and Syndromes (18 papers)
Cited by: Hematology Genetics Rheumatology
Journals: The Lancet Nature Communications Journal of Clinical Oncology
Partner nations: United Kingdom Greece France

In The Last Decade

Marco Bua

31 papers receiving 2.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Adherence Is the Critical Factor for Achieving Molecular Responses in Patients With Chronic Myeloid Leukemia Who Achieve Complete Cytogenetic Responses on Imatinib

2010 674 citations David Marín, Alexandra Bazeos et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Marco Bua

Since Specialization

Citations

This map shows the geographic impact of Marco Bua's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marco Bua with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marco Bua more than expected).

Fields of papers citing papers by Marco Bua

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marco Bua. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marco Bua. The network helps show where Marco Bua may publish in the future.

Co-authorship network of co-authors of Marco Bua

This figure shows the co-authorship network connecting the top 25 collaborators of Marco Bua. A scholar is included among the top collaborators of Marco Bua based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marco Bua. Marco Bua is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Optimal, Off-the-Shelf, CAR-iNKT Cell Platform-Based Immunotherapy for Multiple Myeloma 2023 ·Blood ·(unknown),(unknown),Hongwei Ren,(unknown),(unknown),(unknown),(unknown),Irene Sarkar,(unknown),(unknown),(unknown),Marco Bua,Maria Atta,(unknown),Irene Roberts,Aristeidis Chaidos,Anastasios Karadimitris	0
2	Development of Novel Invariant TCR-Anchored Bispecific Engagers to Enhance Anti-Cancer Activity of iNKT Cells 2023 ·Blood ·(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),Marco Bua,Maria Atta,(unknown),Irene Roberts,Aristeidis Chaidos,Anastasios Karadimitris	2
3	Third primary SARS-CoV-2 mRNA vaccines enhance antibody responses in most patients with haematological malignancies 2022 ·Nature Communications ·Lucy Cook,(unknown),(unknown),(unknown),(unknown),Dragana Milojković,Jane F. Apperley,(unknown),Simone Claudiani,Marco Bua,(unknown),Donald Macdonald,Aristeidis Chaidos,Jiří Pavlů,Nichola Cooper,Sarah Fidler,Paul Randell,Andrew J. Innes	8
4	Chromatin-based, in cis and in trans regulatory rewiring underpins distinct oncogenic transcriptomes in multiple myeloma 2021 ·Nature Communications ·(unknown),(unknown),(unknown),(unknown),Aristeidis Chaidos,Philippa C. May,Xiaolin Xiao,Marco Bua,Maria Atta,Irene Roberts,Holger W. Auner,Evdoxia Hatjiharissi,Maria Papaioannou,Valentina S. Caputo,Ian Sudbery,Anastasios Karadimitris	26
5	Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic myeloid leukemia: implications for early intervention strategies 2013 ·Blood ·(unknown),Gareth Gerrard,Claire Lucas,Dragana Milojković,Philippa C. May,Lihui Wang,Christos Paliompeis,Marco Bua,Alistair Reid,Katayoun Rezvani,Stephen J. O’Brien,Richard E. Clark,John M. Goldman,David Marin	71
6	Is Major Molecular Response a Safe Haven Against Blast Crisis in Cml Patients Treated with Imatinib? 2012 ·Blood ·(unknown),Dragana Milojković,Gareth Gerrard,Letizia Foroni,Jane F. Apperley,Richard Szydlo,Alistair Reid,Marco Bua,Katy Rezvani,John M. Goldman,David Marín	1
7	Can the Combination of the Measurement of BCR-ABL1 Transcript Levels At 3 and 6 Months Improve the Prognostic Value of the 3 Month Measurement? 2012 ·Blood ·(unknown),Gareth Gerrard,Letizia Foroni,Dragana Milojković,Jane F. Apperley,Richard Szydlo,Marco Bua,Alistair Reid,Katy Rezvani,John M. Goldman,David Marín	2
8	Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy 2011 ·Blood ·Amr R. Ibrahim,Lina Eliasson,Jane F. Apperley,Dragana Milojković,Marco Bua,Richard Szydlo,François‐Xavier Mahon,Kasia Kozlowski,Christos Paliompeis,Letizia Foroni,Jamshid S. Khorashad,A. Bazeos,Mathiéu Molimard,Alistair Reid,Katayoun Rezvani,Gareth Gerrard,John M. Goldman,David Marín	246
9	Responses to second-line tyrosine kinase inhibitors are durable: an intention-to-treat analysis in chronic myeloid leukemia patients 2011 ·Blood ·Dragana Milojković,Jane F. Apperley,Gareth Gerrard,Amr R. Ibrahim,Richard Szydlo,Marco Bua,Alistair Reid,Katayoun Rezvani,Letizia Foroni,John M. Goldman,David Marín	49
10	Adherence Is the Critical Factor for Achieving Molecular Responses in Patients With Chronic Myeloid Leukemia Who Achieve Complete Cytogenetic Responses on Imatinibbreakdown → 2010 ·Journal of Clinical Oncology ·David Marín,Alexandra Bazeos,François-Xavier Mahon,Lina Eliasson,Dragana Milojković,Marco Bua,Jane F. Apperley,Richard Szydlo,(unknown),Kasia Kozlowski,Christos Paliompeis,Victoria Latham,Letizia Foroni,Mathiéu Molimard,Alistair Reid,Katy Rezvani,Hugues de Lavallade,(unknown),John M. Goldman,Jamshid S. Khorashad	674
11	Efficacy of tyrosine kinase inhibitors (TKIs) as third-line therapy in patients with chronic myeloid leukemia in chronic phase who have failed 2 prior lines of TKI therapy 2010 ·Blood ·Amr R. Ibrahim,Christos Paliompeis,Marco Bua,Dragana Milojković,Richard Szydlo,Jamshid S. Khorashad,Letizia Foroni,Alistair Reid,Hugues de Lavallade,Katayoun Rezvani,Francesco Dazzi,Jane F. Apperley,John M. Goldman,David Marín	50
12	Long Term Adherence to Imatinib Therapy Is the Critical Factor for Achieving Molecular Responses in Chronic Myeloid Leukemia Patients. 2009 ·Blood ·A. Bazeos,Jamshid S. Khorashad,François‐Xavier Mahon,Lina Eliasson,Dragana Milojković,Marco Bua,Jane F. Apperley,Richard Szydlo,Kasia Kozlowski,Christos Paliompeis,(unknown),Letizia Foroni,Alistair Reid,Hugues de Lavallade,Katy Rezvani,John M. Goldman,David Marín	15
13	Does a rise in the BCR‐ABL1 transcript level identify chronic phase CML patients responding to imatinib who have a high risk of cytogenetic relapse? 2009 ·British Journal of Haematology ·David Marín,Jamshid S. Khorashad,Letizia Foroni,Dragana Milojković,Richard Szydlo,Alistair Reid,Katayoun Rezvani,Marco Bua,John M. Goldman,Jane F. Apperley	18
14	Imatinib for Newly Diagnosed Patients With Chronic Myeloid Leukemia: Incidence of Sustained Responses in an Intention-to-Treat Analysis 2008 ·Journal of Clinical Oncology ·Hugues de Lavallade,Jane F. Apperley,Jamshid S. Khorashad,Dragana Milojković,Alistair Reid,Marco Bua,Richard Szydlo,Eduardo Olavarría,Jaspal Kaeda,John M. Goldman,David Marín	416
15	Finding of Kinase Domain Mutations in Patients With Chronic Phase Chronic Myeloid Leukemia Responding to Imatinib May Identify Those at High Risk of Disease Progression 2008 ·Journal of Clinical Oncology ·Jamshid S. Khorashad,Hugues de Lavallade,Jane F. Apperley,Dragana Milojković,Alistair Reid,Marco Bua,Richard Szydlo,Eduardo Olavarría,Jaspal Kaeda,John M. Goldman,David Marín	144
16	European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor 2008 ·Blood ·David Marín,Dragana Milojković,Eduardo Olavarría,Jamshid S. Khorashad,Hugues de Lavallade,Alistair Reid,Letizia Foroni,Katayoun Rezvani,Marco Bua,Francesco Dazzi,Jiří Pavlů,Matthias Klammer,Jaspal Kaeda,John M. Goldman,Jane F. Apperley	238
17	Long Term Durability of Major Molecular Responses for Patients Treated with Imatinib after Failure of Interferon-Alfa Is Equivalent to That of Patients Achieving Major Molecular Responses to Imatinib as Primary Therapy. 2007 ·Blood ·Hugues de Lavallade,Jamshid S. Khorashad,Marco Bua,Dragana Milojković,Eduardo Olavarría,Alistair Reid,Jaspal Kaeda,John M. Goldman,Jane F. Apperley,David Marín	1
18	Pleural Effusions Associated with Use of Dasatinib in Chronic Myeloid Leukemia May Have an Auto-Immune Pathogenesis. 2007 ·Blood ·(unknown),Hugues de Lavallade,Dragana Milojković,Marco Bua,Jamshid S. Khorashad,John M. Goldman,Jane F. Apperley,David Marín	4
19	Phase I/II trial of adding semisynthetic homoharringtonine in chronic myeloid leukemia patients who have achieved partial or complete cytogenetic response on imatinib 2005 ·Cancer ·David Marín,Jaspal Kaeda,(unknown),(unknown),Marco Bua,Eduardo Olavarría,John M. Goldman,Jane F. Apperley	57
20	Survival of patients with chronic-phase chronic myeloid leukaemia on imatinib after failure on interferon alfa 2003 ·The Lancet ·David Marín,Sarah Marktel,Richard Szydlo,John P. Klein,Marco Bua,Nicola Foot,Eduardo Olavarría,(unknown),Edward Kanfer,John M. Goldman,Jane F. Apperley	27

About Marco Bua

Marco Bua is a scholar working on Hematology, Genetics and Rheumatology, having authored 32 papers that have together received 2.6k indexed citations. Recurring topics across this work include Chronic Myeloid Leukemia Treatments (26 papers), Chronic Lymphocytic Leukemia Research (25 papers) and Eosinophilic Disorders and Syndromes (18 papers). The work is most often cited by research in Hematology (2.3k citations), Genetics (2.0k citations) and Rheumatology (1.3k citations). Marco Bua has collaborated with scholars based in United Kingdom, Greece and France. Frequent co-authors include John M. Goldman, Jane F. Apperley, David Marín, Dragana Milojković, Alistair Reid, Richard Szydlo, Jamshid S. Khorashad, Hugues de Lavallade, Letizia Foroni and Eduardo Olavarría. Their work appears in journals such as The Lancet, Nature Communications and Journal of Clinical Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact